Anmolpreet Gurwal

So we understand that low sac shifts us from the portal hypertensive causes, and it shifts towards a primary peritoneal or systemic process.

So for that, we have the main buckets of infection, autoimmune, malignancy, and organ-specific pathologies, including GI system and kidneys.

autoimmune serocitis, which is seen in SLE and FMF, which can also lead to exudative ascitis.

But we would expect additional systemic features or serological markers, which are absent here.

And autoimmune etiologies are anyways highly unlikely at this age.

Next, we consider malignancy-related ascites, which is one of the most important causes of low SAG fluid, and this would include peritoneal carcinomatosis, mesothelioma, gynecologic malignancies.

They often produce hemorrhagic inflammatory ascites, along with systemic features like weight loss.

The tumor markers were negative, but still, in the clinical context, we may consider this as one of the differentials.

And the other causes we can also be considered pancreatic and gastrointestinal causes such as pancreatic ascites, but they are typically associated with markedly elevated ascitic amylase and a history of pancreatitis, neither of which are present here.

Renal causes like nephrotic syndrome can produce low sag ascites, but this is usually non-inflammatory and non-hemorrhagic, often with generalized edema rather than isolated ascites.

So overall, this is a very complex case and it is difficult to definitively anchor on a single diagnosis.

While myeloproliferative neoplasm-related microvascular presinusoidal hypertension may be present in the background, it is unlikely to be the primary driver of this low sagasitis.

Based on the available data, a malignancy remains an important consideration, but at the same time, the elevated bilirubin in the ascitic fluid introduces an additional layer of complexity, raising concern for a possible biliary or secondary inflammatory process.

So at this stage, I would involve oncology early and evaluate the ascitic fluid for malignant cells, as well as said.

And simultaneously, given the possibility of an infectious process, it is reasonable to continue empiric intravenous antibiotics while further data are obtained.